Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are not being treated with lipid-lowering therapies. So what's the answer? Dr. James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the pharmaceutical industry to manage cholesterol.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Combination Therapy to Manage Lipids
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are not being treated with lipid-lowering therapies. So what's the answer? Dr. James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the pharmaceutical industry to manage cholesterol.
Presenters
Facebook Comments